Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and Ozempic in the U.S. market.
Novo Nordisk Stock Tumbles 20% After Ozempic Maker’s Shock Cut to U.S. Outlook
view original post